LINC01243: A Potential Drug Target and Biomarker (G101929620)

Target Name: LINC01243

NCBI ID: G101929620

LINC01243

Other Name(s): Long intergenic non-protein coding RNA 1243 | long intergenic non-protein coding RNA 1243

LINC01243: A Potential Drug Target and Biomarker

LINC01243 is a non-protein coding RNA (ncRNA) molecule located in chromosome 6p21.2, which has been identified as a potential drug target and biomarker. The RNA molecule has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. LINC01243 has also been associated with various diseases, including cancer and neurodegenerative disorders.

The Discovery of LINC01243 as a Potential Drug Target

LINC01243 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with various diseases. One of the key features of LINC01243 is its ability to interact with several protein molecules, including the protein tyrosine kinase (PTK) signaling pathway. This interaction between LINC01243 and PTK signaling pathway makes it a potential drug target.

LINC01243 has also been shown to play a role in the regulation of cellular adhesion and migration. It has been shown to be involved in the formation of tight junctions, which are critical for maintaining tissue structure and function. LINC01243 has also been shown to be involved in the regulation of cell migration, which is critical for the development and progression of many diseases, including cancer.

Another potential mechanism by which LINC01243 may be a drug target is its association with various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. LINC01243 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the brain. The dysfunction in neurotransmitter release that is associated with these disorders may be related to the dysfunction in LINC01243.

The Potential Use of LINC01243 as a Biomarker

LINC01243 has also been identified as a potential biomarker for several diseases. For example, LINC01243 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancers. This downregulation of LINC01243 may be related to the dysfunction in cell signaling that is associated with cancer.

LINC01243 has also been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases, including cancer. The dysfunction in inflammation that is associated with LINC01243 may be related to its role in regulating the immune response.

Conclusion

In conclusion, LINC01243 is a non-protein coding RNA molecule that has been identified as a potential drug target and biomarker. Its interaction with the PTK signaling pathway and its involvement in various cellular processes, including cell adhesion, migration, and inflammation make it a promising target for drug development. The potential use of LINC01243 as a biomarker for diseases such as cancer and neurodegenerative disorders makes it an attractive candidate for further research.

Protein Name: Long Intergenic Non-protein Coding RNA 1243

The "LINC01243 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01243 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets